<DOC>
	<DOC>NCT02936596</DOC>
	<brief_summary>Biochemical response of primary biliary cholangitis-autoimmune hepatitis overlap syndrome induced by ursodeoxycholic acid only or combination therapy of immunosuppressive agents</brief_summary>
	<brief_title>Remission Induction of Primary Biliary Cholangitis-autoimmune Hepatitis Overlap Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Cholestasis</mesh_term>
	<mesh_term>Cholangitis</mesh_term>
	<mesh_term>Hepatitis, Autoimmune</mesh_term>
	<mesh_term>Liver Cirrhosis, Biliary</mesh_term>
	<mesh_term>Immunosuppressive Agents</mesh_term>
	<mesh_term>Ursodeoxycholic Acid</mesh_term>
	<criteria>1.Patients aged 1870 years; 2.Diagnosed with primary biliary cholangitisautoimmune hepatitis overlap syndrome according to Paris criteria, based on liver biopsy results obtained 3 months before screening; 3.White blood cell count ≥2.5x10^9/L or platelet count ≥50x10^9/L at inclusion; 4.Agreed to participate in the trial, and assigned informed consent. 1. The presence of hepatitis A, B, C, D, or E virus infection; 2. Patients with indications for immunosuppressive treatment at inclusion: serum alanine transaminase(ALT) or aspartate transaminase(AST) ≥10 fold upper limit of normal(ULN)，or serum ALT or AST≥ 5 fold ULN and γglobulin level ≥ 2 fold ULN, or bridging necrosis or multiacinar necrosis on histological examination. 3. Patients with complications of cirrhosis; 4. Patients with previous treatment of immunosuppressive agents or traditional Chinese medicine for more than one month; 5. Primary sclerosing cholangitis,nonalcoholic steatohepatitis,drug induced liver disease or Wilson's disease confirmed by liver biopsy; 6. Pregnant and breeding women; 7. Severe disorders of other vital organs, such as severe heart failure, cancer; 8. Parenteral administration of blood or blood products within 6 months before screening; 9. Recent treatment with drugs having known liver toxicity; 10.Taken part in other clinic trials within 6 months before screening.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>